ImageneBio, Inc. (NASDAQ:IMA) — Market Cap & Net Worth
Market Cap & Net Worth: ImageneBio, Inc. (IMA)
ImageneBio, Inc. (NASDAQ:IMA) has a market capitalization of $56.93 Million ($56.93 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21515 globally and #4829 in its home market, demonstrating a 0.20% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ImageneBio, Inc.'s stock price $5.02 by its total outstanding shares 11374130 (11.37 Million). Also see ImageneBio, Inc. assets under control for a full breakdown of the balance sheet.
ImageneBio, Inc. Market Cap History: 2025 to 2026
ImageneBio, Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $78.48 Million to $57.10 Million (0.00% CAGR). Also see IMA cash generation efficiency for how efficiently the company converts equity into cash flow.
ImageneBio, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ImageneBio, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for ImageneBio, Inc. for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
98.10x
ImageneBio, Inc.'s market cap is 98.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $78.48 Million | $800.00K | -$45.35 Million | 98.10x | N/A |
Competitor Companies of IMA by Market Capitalization
Companies near ImageneBio, Inc. in the global market cap rankings as of September 18, 2026. Review IMA tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to ImageneBio, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
ImageneBio, Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, ImageneBio, Inc.'s market cap moved from $78.48 Million to $ 57.10 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $57.10 Million | -27.25% |
| 2025 | $78.48 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of ImageneBio, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $56.93 Million USD |
| MoneyControl | $56.93 Million USD |
| MarketWatch | $56.93 Million USD |
| marketcap.company | $56.93 Million USD |
| Reuters | $56.93 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ImageneBio, Inc.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerl… Read more